CLINICAL TRIALS PROFILE FOR SANCTURA XR
✉ Email this page to a colleague
All Clinical Trials for Sanctura Xr
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00863551 ↗ | Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial | Completed | Allergan | Phase 4 | 2009-04-01 | This study evaluates the penetration through the blood-brain-barrier of trospium chloride at plasma steady state (Day 10) in elderly subjects with overactive bladder symptoms. Trospium levels in cerebrospinal fluid (CSF) and peak and trough plasma levels will be measured. Baseline and day 10 post-dose neurocognitive testing will be compared using a reliable change index to assess if any study subject shows evidence of a clinically and statistically significant change in memory. |
NCT00986401 ↗ | Safety and Tolerability of Trospium Chloride and Metformin Hydrochloride in Healthy Subjects | Completed | Allergan | Phase 1 | 2009-10-01 | The purpose of this study is to investigate the safety and tolerability of trospium chloride (Sanctura XR™) and metformin hydrochloride (Glucophage) when co-administered. |
NCT01089751 ↗ | Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily | Completed | Allergan | Phase 4 | 2010-03-01 | This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Sanctura Xr
Condition Name
Clinical Trial Locations for Sanctura Xr
Trials by Country
Clinical Trial Progress for Sanctura Xr
Clinical Trial Phase
Clinical Trial Sponsors for Sanctura Xr
Sponsor Name